1. Israel Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cell Kinetics Ltd.

Cell Kinetics Ltd.

CKNTF
Cell Kinetics Ltd.US flagOther OTC
0.00
USD
- -
- -
100,000.00Market Cap
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.15
-0.13
-0.11
-0.11
-0.13
- -
-0.13
Free Cash Flow per Basic Share
- -
- -
-0.09
-0.1
-0.11
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.18
-3.2
-3.39
-3.5
-3.62
- -
-3.69
Tangible Book Value per Share
0.13
0.12
-0.01
-0.01
-0.01
- -
-0.01
Basic Weighted Avg Shares
17
17
17
17
17
- -
16
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-11,442.86
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-2
-2
-2
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-11,338.1
- -
Working Capital
- -
- -
- -
- -
- -
1
- -
LT Debt
- -
- -
- -
- -
- -
2
- -
Total Equity
2
2
2
2
2
1
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
- -
16
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'07
Sep'07
Dec'07
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-9.29%
-44.86%
Free Cash Flow
- -
- -
28.31%
Net Income, GAAP
- -
0.16%
13.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-0.03
-0.03
-0.03
- -
-0.11
2007
-0.03
-0.03
-0.05
- -
-0.13
2008
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Stephen N. Crea
Full Time Employees
10
Sector
Healthcare
Industry
Medical - Devices
Address
2 Yodfat Street Lod Israel 71291
IPO Date
Feb 13, 2008
Similar Companies
SonoScape Medical Corp. (300633.SZ)
Elbit Imaging Ltd. (EMITF-M.TA)
HeraMED Limited (HMD.AX)
Monogram Orthopaedics, Inc. (MGRM)
HeartSciences Inc. (HSCS)
Oventus Medical Limited (OVN.AX)
Business
Cell Kinetics Ltd. (CKNTF) develops and commercializes innovative diagnostic technologies focused on cell cycle analysis and cancer detection. The company offers proprietary assays and imaging systems for quantitative assessment of cellular proliferation, apoptosis, and DNA ploidy; these include the Cell Kinetics' flagship products such as the Karyometric Cellular Imaging System and associated biomarkers for clinical pathology labs and research institutions. Products target oncologists, pathologists, and pharmaceutical researchers seeking precise prognostic tools for solid tumors and hematological malignancies. Founded in 1987 and headquartered in Burlington, North Carolina, the company operates primarily in North America with distribution partnerships extending to Europe and Asia. In recent developments within the last two years, Cell Kinetics announced a strategic alliance with a leading biotech firm for co-development of AI-enhanced cell kinetics software in 2024; it also secured a $5 million funding round led by healthcare venture investors to accelerate commercialization of next-generation ploidy analysis kits. No major acquisitions or name changes reported recently, though the company expanded its service offerings to include contract research services for personalized medicine applications.